MULTIPLE SCLEROSIS: Progressive multifocal leukoencephalopathy risk stratification

    loading  Checking for direct PDF access through Ovid

Abstract

A compelling need exists for a more reliable risk evaluation of natalizumab-associated progressive multifocal leukoencephalopathy (PML). A new report proposes a refined protocol that uses updated patient-based data and cumulative risk evaluation to provide an improved assessment of the annual risk of PML for patients positive for JC virus.

Refers to Ho, P. R. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 16, 925–933 (2017)

Related Topics

    loading  Loading Related Articles